

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

208945Orig1s000

Trade Name: Xepi Cream, 1%

Generic or Proper Name: ozenoxacin

Sponsor: Ferrer Internacional S.A.

Approval Date: December 11, 2017

Indication: For the topical treatment of impetigo in adults, adolescents and children 2 months and older.

CENTER FOR DRUG EVALUATION AND RESEARCH

208945Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	X
Labeling	X
REMS	
Summary Review	X
Officer/Employee List	X
Office Director Memo	
Cross Discipline Team Leader Review	
Clinical Review(s)	X
Product Quality Review(s)	X
Non-Clinical Review(s)	X
Statistical Review(s)	X
Clinical Microbiology / Virology Review(s)	X
Clinical Pharmacology Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	X
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

208945Orig1s000

APPROVAL LETTER



NDA 208945

NDA APPROVAL

Ferrer Internacional S.A.
c/o Prosoft Clinical
Attention: Robert W. Babilon, MS, MBA
Vice President, Regulatory Affairs and Quality Assurance
996 Old Eagle School Road, Suite 1106
Wayne, PA 19087

Dear Mr. Babilon:

Please refer to your New Drug Application (NDA) dated June 23, 2016, received June 23, 2016, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Xepi (ozenoxacin) Cream, 1%.

We acknowledge receipt of your amendment dated July 17, 2017, which constituted a complete response to our June 22, 2017, action letter.

This new drug application provides for the use of Xepi (ozenoxacin) Cream, 1% for the topical treatment of impetigo in adults, adolescents and children 2 months and older.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

LABELING

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The final printed labeling must be identical to the enclosed labeling (package insert, SKU immediate container labels, and SKU carton labels), and must be in the "Drug Facts" format (21 CFR 201.66), where applicable.

The final printed labeling should be submitted electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3)*. For administrative purposes, designate this submission "**Final Printed Labeling for approved NDA 208945.**" Approval of this submission by FDA is not required before the labeling is used.

CARTON AND IMMEDIATE CONTAINER LABELS

We acknowledge your November 27, 2017, submission containing final printed carton and container labels.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

ADVISORY COMMITTEE

Your application for Xepi (ozenoxacin) Cream, 1% was not referred to an FDA advisory committee because outside expertise was not necessary; there were no issues that would benefit from advisory committee discussion.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

This product is appropriately labeled for use in all relevant pediatric populations. Therefore, no additional pediatric studies are needed at this time.

We are waiving the pediatric study requirement for ages < 2 months because necessary studies are impossible or highly impracticable. This is because the number of pediatric patients is so small or is geographically dispersed.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

MEDWATCH-TO-MANUFACTURER PROGRAM

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at <http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm>.

If you have any questions, call Eva Zuffova, PhD, Regulatory Health Project Manager, at (301) 796-0697.

Sincerely,

{See appended electronic signature page}

John Farley, MD, MPH
Deputy Director
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):

Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOHN J FARLEY
12/11/2017